The Cure That Works
Singapore's cheaper, better way
Description
The United States spends roughly 17 to 18 percent of its economic output on health care — more than any country on Earth, close to twice the average of comparable wealthy nations. For all that money, Americans do not live longer. Life expectancy trails most of the developed world, and tens of millions worry about the bill before they worry about the diagnosis. Sean Masaki Flynn, an economist who teaches at Scripps College, opens his book The Cure That Works with a simple, uncomfortable observation: the country that pays the most is not getting the most, and everyone has quietly accepted that this is just how medicine works.
Then he points somewhere unexpected. Not to Canada, not to Britain, not to the single-payer systems that dominate the American argument. He points to Singapore, a small city-state that spends around 4 to 5 percent of its output on health care — a fraction of the American figure — while posting some of the best health outcomes in the world. Longer lives, lower infant mortality, and citizens who are not bankrupted by a hospital stay. The number is so far below the American one that it sounds like a typo.
Flynn's argument is that this is no accident and no cultural fluke. Singapore built its system on purpose, around a handful of blunt mechanical rules that make prices visible and make patients spend as if the money were their own — because, in large part, it is. His book is an attempt to reverse-engineer those rules and ask whether America, which loves markets everywhere else, could bring them into the one place it never has.
The question we’re asking : Can a country spend far less on health care and still get better results — and if so, how does Singapore actually pull it off?What we’ll see : How a small city-state turned a handful of blunt market rules into the best deal in medicine, and what stops America from copying it.
Table of contents
01Chapter 1 — A country spending a fraction and living longer
The comparison Flynn keeps returning to is almost too lopsided to feel fair. The United States pours something close to 18 percent of everything it produces into health care. Singapore spends roughly a quarter of that share. If the arrangement were simply cheaper, the natural assumption would be that Singaporeans get less — shorter lives, worse care, longer waits, the usual price of thrift. The data say the opposite. Singapore posts life expectancy above 83 years, among the highest anywhere, and infant mortality low enough to sit at the top of every ranking. Cheaper and better, at the same time.
This is the wall the book runs at, because it violates the assumption that quietly governs the entire American conversation. Everyone from left to right tends to believe there is a trade-off: you can have low cost or high quality, and the fight is only about where to land. Flynn's whole project is to argue that Singapore has broken the trade-off, and that the reason is structural rather than mysterious. It is not that Singaporeans are healthier by nature, or that a small rich city is easy to run. Other small rich places spend far more and do worse.
02Chapter 2 — The rule that forces prices into the open
The first mechanism Flynn examines is the one Americans find hardest to believe exists: in Singapore, you can find out what something costs before you buy it. Hospitals are required to publish their prices. The Ministry of Health posts what different facilities charge for common procedures — a knee replacement, a delivery, a cataract removal — so a patient can compare a public hospital against a private one and see the gap in real numbers. This sounds mundane. In the context of American medicine it is close to revolutionary.
The reason it matters is that price transparency is the precondition for everything else. A market cannot discipline prices if no one knows the prices. In the United States, the same procedure at the same hospital can carry wildly different charges depending on the insurer, and patients routinely learn the cost only after the fact, on a bill they cannot decode. Flynn's point is that this opacity is not a side effect; it is what lets prices float free of any competitive pressure. When nobody can compare, nobody competes, and there is no ceiling on what gets charged.
03Chapter 3 — Savings accounts that make patients care about the bill
The engine of the Singapore system is a program called Medisave. Every working citizen is required to divert a portion of income into a personal, tax-advantaged medical savings account. The money is theirs — it accumulates, it earns interest, and what they do not spend on health care they eventually keep, passing to heirs when they die. This is the piece that makes the published prices matter. When patients spend from an account with their own name on it, the cost of care stops being someone else's problem.
Flynn treats this as the fix for the deepest distortion in health economics, the one economists call moral hazard. When a third party — an insurer, an employer, a government — pays the bill, the patient has no reason to weigh whether a treatment is worth its cost, and the provider has no reason to hold the price down. Demand loses its brakes. American insurance, by design, insulates patients from prices for almost everything, routine and catastrophic alike, and the predictable result is spending that climbs without resistance. Medisave reintroduces the brake for ordinary care by handing the patient the money and the decision at once.
04Chapter 4 — The catastrophic coverage that catches everyone
The counterweight is a layered safety net that Flynn insists is inseparable from the rest. On top of Medisave sits MediShield Life, a national insurance program that covers large, catastrophic bills — the events too big for any personal account to absorb. Below both sits Medifund, a government endowment that pays for those who cannot pay at all. The savings accounts handle the everyday, catastrophic insurance handles the disasters, and a backstop handles the destitute. Nobody is meant to fall through.
The reason this matters is that it answers the standard objection before it can be raised. Critics of consumer-driven health care point out, correctly, that markets punish the sick and the poor, who consume the most care and can least afford it. Flynn's response, through Singapore, is that this is exactly why the market is confined to the zone where it works. Patients shop and economize for routine care, where price sensitivity is healthy. They are shielded, fully, from the ruinous events where price sensitivity would be monstrous. The system does not ask a cancer patient to comparison-shop chemotherapy.
05Conclusion
The number that opens the book — 4 to 5 percent of output against America's 18 — turns out not to be a fact about Singapore's wealth or size or culture. It is the sum of a few deliberate rules: prices posted in the open, savings accounts that make patients spend as if the money were theirs because it is, catastrophic insurance for the events no account could cover, and a public backstop for those with nothing. Each piece is unremarkable on its own. Together they produce a place that pays a quarter of what America pays and lives longer for it.